[1]
|
Chowdhary, V.R., Crowson, C.S., Poterucha, J.J., et al. (2008) Liver Involvement in Systemic Lupus Erythematosus: Case Review of 40 Patients. The Journal of Rheumatology, 35, 2159-2164. https://doi.org/10.3899/jrheum.080336
|
[2]
|
Liu, Y., Yu, J., Oaks, Z., et al. (2015) Liver Injury Correlates with Biomarkers of Autoimmunity and Disease Activity and Represents an Organ System Involvement in Patients with Sys-temic Lupus Erythematosus. Clinical Immunology, 160, 319-327. https://doi.org/10.1016/j.clim.2015.07.001
|
[3]
|
Afzal, W., Haghi, M., Hasni, S.A. and Newman, K.A. (2020) Lu-pus Hepatitis, More than Just Elevated Liver Enzymes. The Scandinavian Journal of Rheumatology, 49,427-433. https://doi.org/10.1080/03009742.2020.1744712
|
[4]
|
Takahashi, A., Abe, K., Saito, R., et al. (2013) Liver Dys-function in Patients with Systemic Lupus Erythematosus. Internal Medicine, 52, 1461-1465. https://doi.org/10.2169/internalmedicine.52.9458
|
[5]
|
Yu, H., Han, H., Li, J., et al. (2019) Alpha-Hydroxybutyrate Dehydrogenase as a Biomarker for Predicting Systemic Lupus Erythematosus with Liver Injury. International Im-munopharmacology, 77, Article ID: 105922.
https://doi.org/10.1016/j.intimp.2019.105922
|
[6]
|
Wang, C.-R. and Tsai, H.-W. (2022) Autoimmune Liver Dis-eases in Systemic Rheumatic Diseases. World Journal of Gastroenterology, 28, 2527-2545. https://doi.org/10.3748/wjg.v28.i23.2527
|
[7]
|
Cai, R., Liu, M., Hu, Y., et al. (2017) Identification of Adverse Drug-Drug Interactions through Causal Association Rule Discovery from Spontaneous Adverse Event Reports. Artificial Intelligence in Medicine, 76, 7-15.
https://doi.org/10.1016/j.artmed.2017.01.004
|
[8]
|
Ohira, H. (2004) High Frequency of Anti-Ribosomal P Anti-body in Patients with Systemic Lupus Erythematosus-Associated Hepatitis. Hepatology Research, 28, 137-139. https://doi.org/10.1016/j.hepres.2003.11.008
|
[9]
|
Calich, A.L., Viana, V.S.T., Cancado, E., et al. (2013) An-ti-Ribosomal P Protein: A Novel Antibody in Autoimmune Hepatitis. Liver International, 33, 909-913. https://doi.org/10.1111/liv.12155
|
[10]
|
Piga, M., Vacca, A., Porru, G., et al. (2010) Liver Involvement in Systemic Lupus Erythematosus: Incidence, Clinical Course and Outcome of Lupus Hepatitis. Clinical and Experimental Rheuma-tology, 28, 504-510.
|
[11]
|
Barber, M., et al. (2021) Global Epidemiology of Systemic Lupus Erythematosus. Nature Re-views. Rheumatology, 17, 515-532. https://doi.org/10.1038/s41584-021-00668-1
|
[12]
|
Isenberg, D.A., Rahman, A., Allen, E., et al. (2004) BILAG 2004. Development and Initial Validation of an Updated Version of the British Isles Lu-pus Assessment Group’s Disease Activity Index for Patients with Systemic Lupus Erythematosus. Rheumatology, 44, 902-906. https://doi.org/10.1093/rheumatology/keh624
|
[13]
|
Manderson, A.P., Botto, M. and Walport, M.J. (2004) The Role of Complement in the Development of Systemic Lupus Erythematosus. Annual Review of Immunology, 22, 431-456.
https://doi.org/10.1146/annurev.immunol.22.012703.104549
|
[14]
|
Drenkard, C., Villa, A.R., Reyes, E., et al. (1997) Vasculitis in Systemic Lupus Erythematosus. Lupus, 6, 235-242.
https://doi.org/10.1177/096120339700600304
|
[15]
|
Ramos-Casals, M., Nardi, N., Lagrutta, M., et al. (2006) Vas-culitis in Systemic Lupus Erythematosus: Prevalence and Clinical Characteristics in 670 Patients. Medicine, 85, 95-104. https://doi.org/10.1097/01.md.0000216817.35937.70
|
[16]
|
Patel, A. and Perl, A. (2022) Redox Control of Integ-rin-Mediated Hepatic Inflammation in Systemic Autoimmunity. Antioxidants & Redox Signaling, 36, 367-388. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982133/
|
[17]
|
Bessone, F. (2014) Challenge of Liver Disease in Systemic Lupus Erythematosus: Clues for Diagnosis and Hints for Pathogenesis. World Journal of Hepatology, 6, 394-409. https://doi.org/10.4254/wjh.v6.i6.394
|
[18]
|
Arnett, F.C. and Reichlin, M. (1995) Lupus Hepatitis: An Under-Recognized Disease Feature Associated with Autoantibodies to Ribosomal P. The American Journal of Medicine, 99, 465-472.
https://doi.org/10.1016/S0002-9343(99)80221-6
|
[19]
|
Willeke, P., Schlüter, B., Limani, A., et al. (2016) Liver In-volvement in ANCA-Associated Vasculitis. Clinical Rheumatology, 35, 387-394. https://doi.org/10.1007/s10067-015-2882-5
|
[20]
|
González-Regueiro, J.A., Cruz-Contreras, M., Merayo-Chalico, J., et al. (2020) Hepatic Manifestations in Systemic Lupus Erythematosus. Lupus, 29, 813-824. https://doi.org/10.1177/0961203320923398
|
[21]
|
Solela, G. and Daba, M. (2023) Budd-Chiari Syndrome as an Ini-tial Presentation of Systemic Lupus Erythematosus Associated with Antiphospholipid Syndrome: A Case Report with Review of the Literature. Open Access Rheumatology: Research and Reviews, 15, 139-143. https://doi.org/10.2147/OARRR.S425535
|
[22]
|
Zheng, R.-H., et al. (2013) Clinical and Immunopathological Fea-tures of Patients with Lupus Hepatitis. Chinese Medical Journal, 126, 260-266. https://doi.org/10.3760/cma.j.issn.0366-6999.20121153
|
[23]
|
Fang, X., Zaman, M.H., Guo, X., et al. (2018) Role of Hepatic Deposited Immunoglobulin G in the Pathogenesis of Liver Damage in Systemic Lupus Erythematosus. Fron-tiers in Immunology, 9, Article No. 1457.
https://doi.org/10.3389/fimmu.2018.01457
|
[24]
|
韩晓晓, 邓国民. 狼疮血清IgG对系统性红斑狼疮多器官损害的作用机制[C]//中国免疫学会. 第十四届全国免疫学学术大会论文摘要汇编. 2021: 377.
|
[25]
|
Matsumoto, T., Kobayashi, S., Shimizu, H., et al. (2000) The Liver in Collagen Diseases: Pathologic Study of 160 Cases with Particular Reference to Hepatic Arteritis, Primary Biliary Cirrhosis, Autoimmune Hepatitis and Nodular Regenerative Hyperplasia of the Liver: Liver in Collagen Diseases. Liver, 20, 366-373.
https://doi.org/10.1034/j.1600-0676.2000.020005366.x
|
[26]
|
Haslock, I. (1974) Spontaneous Rupture of the Liver in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 33, 482-484. https://doi.org/10.1136/ard.33.5.482
|
[27]
|
Krauser, R.E. (1976) Spontaneous Rupture of the Spleen in Systemic Lupus Erythematosus. JAMA, 236, 1149.
|
[28]
|
You, H., Peng, L., Zhao, J., et al. (2020) Clinical Characteristics of Sys-temic Lupus Erythematosus with Cirrhosis. Journal of Immunology Research, 2020, Article ID: 2156762. https://doi.org/10.1155/2020/2156762
|
[29]
|
Zhang, L., Yin, L., Lv, W., et al. (2023) Clinical Analysis of Patients with Systemic Lupus Erythematosus Complicated with Liver Failure. Clinical Rheumatology, 42, 1545-1553. https://doi.org/10.1007/s10067-023-06524-9
|
[30]
|
Efe, C., Purnak, T., Ozaslan, E., et al. (2011) Autoimmune Liver Disease in Patients with Systemic Lupus Erythematosus: A Retrospective Analysis of 147 Cases. Scandinavian Journal of Gastroenterology, 46, 732-737.
https://doi.org/10.3109/00365521.2011.558114
|
[31]
|
中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021) [J]. 中华肝脏病杂志, 2022, 30(5): 482-492.
https://doi.org/10.3760/cma.j.cn112138-20211112-00796-1
|
[32]
|
Heneghan, M.A., Yeoman, A.D., Verma, S., et al. (2013) Autoimmune Hepatitis. The Lancet, 382, 1433-1444.
https://doi.org/10.1016/S0140-6736(12)62163-1
|
[33]
|
Arvaniti, P., Giannoulis, G., Gabeta, S., et al. (2020) Belimumab Is a Promising Third-Line Treatment Option for Refractory Autoimmune Hepatitis. JHEP Reports, 2, Article ID: 100123. https://doi.org/10.1016/j.jhepr.2020.100123
|
[34]
|
Kolev, M., Sarbu, A.-C., Möller, B., et al. (2023) Belimumab Treatment in Autoimmune Hepatitis and Primary Biliary Cholangitis—A Case Series. Journal of Transla-tional Autoimmunity, 6, Article ID: 100189.
https://doi.org/10.1016/j.jtauto.2023.100189
|
[35]
|
Kottyan, L.C., Zoller, E.E., Bene, J., et al. (2015) The IRF5-TNPO3 Association with Systemic Lupus Erythematosus Has Two Components That Other Autoimmune Disor-ders Variably Share. Human Molecular Genetics, 24, 582-596.
https://doi.org/10.1093/hmg/ddu455
|
[36]
|
Ebert, E.C. and Hagspiel, K.D. (2011) Gastrointestinal and Hepatic Man-ifestations of Systemic Lupus Erythematosus. Journal of Clinical Gastroenterology, 45, 436-441. https://doi.org/10.1097/MCG.0b013e31820f81b8
|
[37]
|
Li, L., Jiang, W. and Wang, J. (2007) Clinical Analysis of 275 Cases of Acute Drug-Induced Liver Disease. Frontiers of Medicine in China, 1, 58-61. https://doi.org/10.1007/s11684-007-0012-8
|
[38]
|
Gebreselassie, A., Aduli, F. and Howell, C.D. (2019) Rheumato-logic Diseases and the Liver. Clinics in Liver Disease, 23, 247-261. https://doi.org/10.1016/j.cld.2018.12.007
|
[39]
|
Visser, K., Katchamart, W., Loza, E., et al. (2009) Multinational Ev-idence-Based Recommendations for the Use of Methotrexate in Rheumatic Disorders with a Focus on Rheumatoid Ar-thritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists in the 3E Initiative. Annals of the Rheumatic Diseases, 68, 1086-1093. https://doi.org/10.1136/ard.2008.094474
|
[40]
|
Conway, R. and Carey, J.J. (2017) Risk of Liver Disease in Metho-trexate Treated Patients. World Journal of Hepatology, 9, 1092-1100. https://doi.org/10.4254/wjh.v9.i26.1092
|
[41]
|
Lee, Y.H., Bae, S.-C. and Song, G.G. (2013) Hepatitis B Virus Reac-tivation in HBsAg-Positive Patients with Rheumatic Diseases Undergoing Anti-Tumor Necrosis Factor Therapy or DMARDs. International Journal of Rheumatic Diseases, 16, 527-531. https://doi.org/10.1111/1756-185X.12154
|
[42]
|
Chen, M.-H., Chen, M.-H., Liu, C.-Y., et al. (2016) Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment. Journal of Infectious Diseases, 215, 566-573. https://doi.org/10.1093/infdis/jiw606
|
[43]
|
Chen, M.-H., Chen, M.-H., Chou, C.-T., et al. (2020) Low but Long-Lasting Risk of Reversal of Seroconversion in Patients with Rheumatoid Arthritis Receiving Immunosuppressive Therapy. Clinical Gastroenterology and Hepatology, 18, 2573-2581.e1. https://doi.org/10.1016/j.cgh.2020.03.039
|
[44]
|
Yeo, W., Zee, B., Zhong, S., et al. (2004) Comprehensive Analysis of Risk Factors Associating with Hepatitis B Virus (HBV) Reactivation in Cancer Patients Undergoing Cytotoxic Chem-otherapy. British Journal of Cancer, 90, 1306-1311. https://doi.org/10.1038/sj.bjc.6601699
|
[45]
|
Chen, M.-H., Wu, C.-S., Chen, M.-H., et al. (2021) High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythe-matosus. International Journal of Molecular Sciences, 22, Article No. 9116.
https://doi.org/10.3390/ijms22179116
|
[46]
|
You, H., Wang, F., Li, T., et al. (2023) Guidelines for the Prevention and Treatment of Chronic Hepatitis B (Version 2022). Journal of Clinical and Translational Hepatology, 11, 1425-1442. https://doi.org/10.14218/JCTH.2023.00320
|
[47]
|
Huang, D., Aghdassi, E., Su, J., et al. (2012) Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology, 39, 254-261.
https://doi.org/10.3899/jrheum.110310
|
[48]
|
Maiorino, M.I., Bellastella, G., Giugliano, D., et al. (2017) Cooling down Inflammation in Type 2 Diabetes: How Strong Is the Evidence for Cardiometabolic Benefit? Endocrine, 55, 360-365.
https://doi.org/10.1007/s12020-016-0993-7
|
[49]
|
Qiao, X., Zhou, Z.-C., Niu, R., et al. (2019) Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism. Frontiers in Pharmacology, 10, Article No. 855.
https://doi.org/10.3389/fphar.2019.00855
|
[50]
|
Rempenault, C., Combe, B., Barnetche, T., et al. (2018) Metabolic and Cardiovascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases, 77, 98-103.
|